C4 Therapeutics Inc. (CCCC) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    C4 Therapeutics Inc.

    NASDAQ: CCCC · Real-Time Price · USD
    2.72
    0.05 (1.87%)
    At close: Sep 05, 2025, 3:59 PM
    2.77
    1.84%
    After-hours: Sep 05, 2025, 05:57 PM EDT

    C4 Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 35.58M 20.76M 31.1M 45.78M
    Cost of Revenue
    		 7.89M 7.74M 7.57M 2.91M
    Gross Profit
    		 35.58M 13.02M 23.52M 42.88M
    Operating Income
    		 -119.61M -139.03M -129.53M -82.13M
    Interest Income
    		 14.43M 9.81M 3.58M 387K
    Pretax Income
    		 -105.19M -131.21M -128.18M -83.89M
    Net Income
    		 -105.32M -132.49M -128.18M -83.89M
    Selling & General & Admin
    		 42.12M 42.08M 42.79M 33.25M
    Research & Development
    		 110.64M 117.71M 117.84M 94.67M
    Other Expenses
    		 2.44M -7.74M -7.57M -2.91M
    Operating Expenses
    		 155.2M 152.05M 153.06M 125.01M
    Interest Expense
    		 n/a 1.37M 2.22M 2.15M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 155.2M 159.79M 160.63M 127.92M
    Income Tax Expense
    		 131K 1.28M -1.68M 2.15M
    Shares Outstanding (Basic)
    		 69.37M 49.64M 48.86M 46.04M
    Shares Outstanding (Diluted)
    		 69.37M 49.64M 48.86M 46.04M
    EPS (Basic)
    		 -1.52 -2.67 -2.62 -1.82
    EPS (Diluted)
    		 -1.52 -2.67 -2.62 -1.82
    EBITDA
    		 -103.37M -122.1M -124.28M -78.84M
    EBIT
    		 -105.19M -129.84M -125.96M -81.75M
    Depreciation & Amortization
    		 1.82M 7.74M 1.68M 2.91M

    Add to Watchlist